KIYATEC, Inc., a South Carolina startup based on technology developed at Clemson University, has recently announced the $3 million initial closing of the company’s B2 financing round. In addition to the funding, KIYATEC has welcomed LabCorp as a new investor. LabCorp’s investment in KIYATEC is of particular significance because of their expertise in oncology and their preclinical and clinical development strengths. With these new developments, KIYATEC is poised to sharpen their ongoing clinical study, 3D-PREDICT.
An innovator in cancer treatment, KIYATEC works to change the future of cancer care through predicting how cancer patients respond to drug therapies. In the past few months, KIYATEC has gained significant momentum. They have demonstrated leading capabilities in modeling and prediction response to immune-oncology therapies at the 110th Annual Meeting of the American Association for Cancer Research (AACR). On April 10th, they were one of 20 startups chosen to participate in the 2019 University Innovation & Entrepreneurship Showcase. Most notably, in 2019 KIYATEC has added three clinical sites to its 3D-PREDICT study and expects to add additional sites soon.
For more information on KIYATEC, click here.